Advisor Group’s Adaptimmune Therapeutics ADAP Stock Holding History

Advisor Group’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$0	Hold	400	–	–	﹤0.01%	5280
2019 Q3	$1K	Hold	400	–	–	﹤0.01%	5068
2019 Q2	$2K	Hold	400	–	–	﹤0.01%	4944
2019 Q1	$2K	Hold	400	–	–	﹤0.01%	4931
2018 Q4	$2K	Sell	400 -16,209	-98%	-$120K	﹤0.01%	4793
2018 Q3	$225K	Buy	16,609 +867	+6%	+$9.09K	﹤0.01%	2064
2018 Q2	$186K	Buy	15,742 +14,942	+1,868%	+$186K	﹤0.01%	2031
2018 Q1	$9K	Hold	800	–	–	﹤0.01%	4126
2017 Q4	$5K	Hold	800	–	–	﹤0.01%	4377
2017 Q3	$7K	Buy	+800	New	+$5K	﹤0.01%	4113

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Advisor Group's ADAP Position: Q4 2019 in Review

Advisor Group held its Adaptimmune Therapeutics (ADAP) position steady in Q4 2019 at 400 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5280.

Advisor Group first reported a position in ADAP in Q3 2017 and has held it in 10 quarters since. The position peaked at $225K in Q3 2018. 43 funds tracked by Wall St. Rank hold ADAP as of Q4 2019.

Advisor Group held 400 shares of Adaptimmune Therapeutics worth $0 as of Q4 2019.
Advisor Group left its Adaptimmune Therapeutics share count unchanged in Q4 2019.
Adaptimmune Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #5280 holding.
Advisor Group first reported a position in Adaptimmune Therapeutics in Q3 2017 and has held it in 10 quarters since.
Advisor Group's Adaptimmune Therapeutics position peaked at $225K in Q3 2018.
43 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.